Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure

Medical Hypotheses

Volumn 59, Issue 3, 2002, Pages 297-301

  Aronson, Doron ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

AGING; ANGIOPLASTY; ARTERY INJURY; ATHEROSCLEROSIS; CELL PROLIFERATION; CHEMOTAXIS; DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KIDNEY FAILURE; MONOCYTE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR TISSUE;

EID: 0036735615     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00172-X     Document Type: Article

References (51)

1. Advances in coronary angioplasty
2. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement
3. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting
4. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients
5. Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis
6. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus
7. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina
8. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty
9. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
10. Multivessel balloon angioplasty should be abandoned in diabetic patients!
11. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study
12. The comparative pathobiology of atherosclerosis and restenosis
13. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study
14. Pathology of acute and chronic coronary stenting in humans
15. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses
16. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neomtimal hyperplasia
17. Monocyte recruitment and neomtimal hyperplasia in rabbits. Coupled inhibitory effects of heparin
18. Restenosis revisited - New targets, new therapies
19. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
20. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms
21. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
22. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
23. Advanced glycosylation end products in patients with diabetic nephropathy
24. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications
25. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
26. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia
27. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
28. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
29. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits
30. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
31. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
32. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells
33. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease
34. RAGE: A novel cellular receptor for advanced glycation end products
35. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells
36. Regulation of human mononuclear phagocyte migration by cell surface- binding proteins for advanced glycation end products
37. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues
38. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging
39. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins
40. Cachectin/TNF and 1L-1 induced by glucose-modified proteins: Role in normal tissue remodeling
41. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic-vasculopathy and atherosclerosis
42. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells
43. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
44. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo
45. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries
46. Receptor-mediated endothelial cell dysfunction in diabetic vasculopalhy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
47. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
48. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model
49. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products
50. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
51. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking